Gilead Sciences has announced a strategic partnership with Genesis Therapeutics, aimed at using AI to discover and develop ...

Gilead Sciences, Inc. (Nasdaq: GILD) and Genesis Therapeutics, Inc. announced today that the companies have entered into a ...

Gilead Sciences, Inc. and Genesis Therapeutics, Inc. have announced that the companies have entered into a strategic ...

Twinning this cutting-edge cell therapy science with the expertise of Gilead in HIV and hepatitis ... has confirmed that Kite's R&D as well as its commercial operations will remain based in ...

Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial ... and Ribo Life Science and is an advisory board member, received speaker’s ...

Proceeds to support continued development and commercialization of Endocrine Rare Disease products, including the Yorvipath U.S. commercial launch, and general corporate purposesNEW YORK and ...

Daniel Geffken appointed Chief Financial Officer ad interim Mike Campbell appointed Chief Commercial Officer Three senior leaders appointed for Biometrics, Clinical Operations and Market Access ...